Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019

急性リンパ性白血病/急性リンパ芽球性白血病治療薬の世界市場

◆タイトル:Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019
◆商品コード:IRTNTR7891
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年11月11日
◆ページ数:65
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、急性リンパ性白血病/急性リンパ芽球性白血病治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、急性リンパ性白血病/急性リンパ芽球性白血病治療薬の世界市場規模及び予測、種類別分析、投与経路(ROA)別分析、市場シェア、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

[Global Acute Lymphocytic Leukemia Market 2015-2019]
Covering: An in-depth study of the acute lymphocytic leukemia market and segmentation by route of administration (oral and parenteral), by type of molecules (biologics and small molecules), and by geography (the Americas, EMEA, and APAC). The report also presents a detailed analysis of the top companies operating in the market, including Amgen, Bristol-Myers Squibb, and Novartis.

[Market landscape of acute lymphocytic leukemia]
Acute lymphocytic leukemia or acute lymphoblastic leukemia, is a malignancy of the blood cells that affects the lymphoblasts or leukemic blasts, which witnesses an uncontrolled cell division. The main symptoms a patient exhibits are weakness, tiredness, dizziness, fever, shortness of breath, frequent infections, bruising, and bleeding.

Currently, the disease cannot be cured completely but the risk can be reduced by administering medication.

Technavio’s market research analysts expect the global acute lymphocytic leukemia market to grow at a steady rate and post a CAGR of over 4% during the forecast period. One of the major factors contributing to the growth of the market is the provision for orphan drugs. For instance, in the US, orphan designation for a drug means incentives like tax credits for qualified clinical testing, exemption from prescription drug user fees unless indicated for additional non-orphan indications, and market exclusivity for seven years.

Segmentation of the acute lymphocytic leukemia market by route of administration
• Oral
• Parenteral

Many medications are administered through the oral route to guarantee a systemic effect. The oral route is a sub-division of enteral administration and is considered to be one of the safest and most preferred routes of drug administration.

Geographical segmentation of the acute lymphocytic leukemia market
• Americas
• APAC
• EMEA

With a share of over 49%, the Americas dominated the acute lymphocytic leukemia market, with the US being the major revenue contributor. The Americas is closely followed by the EMEA and the APAC region and the market is expected to follow a similar trend during the forecast period.

[Competitive landscape and key vendors]
The acute lymphocytic leukemia market is marked by the presence of both global and local drug manufacturers with varied product portfolios containing generic and off- label drugs as well as branded therapies. Besides, the high level of unmet medical need is expected to give a platform to the vendors to develop products to cater to relevant areas and enhance their market shares.

Primary vendors in this market are –
• Amgen
• Bristol-Myers Squibb
• Novartis

Other prominent vendors included in this report are Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Sigma-Tau Pharmaceuticals.

Key questions answered in the report include
• What will the market size and the growth rate be in 2019?
• What are the key factors driving the global acute lymphocytic leukemia market?
• What are the key market trends impacting the growth of the global acute lymphocytic leukemia market?
• What are the challenges to market growth?
• Who are the key vendors in the global acute lymphocytic leukemia market?
• What are the market opportunities and threats faced by the vendors in the global acute lymphocytic leukemia market?
• What are the trending factors influencing the market shares of the Americas, EMEA, and APAC?
• What are the key outcomes of the five forces analysis of the global acute lymphocytic leukemia market?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology
Research methodology
Economic indicators

PART 05: Introduction
Key market highlights

PART 06: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 07: Disease overview
Etiology and risk factors
Pathophysiology
Symptoms
Epidemiology
Classification
Diagnosis
Treatment and management

PART 08: Market segmentation by route of administration
Oral
Parenteral

PART 09: Market segmentation by type of molecules
Biologics
Small molecules

PART 10: Geographical segmentation
Global acute lymphocytic leukemia therapeutics market by geography 2014
Acute lymphocytic leukemia market in Americas
Acute lymphocytic leukemia market in EMEA
Acute lymphocytic leukemia market in APAC

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape
Competitive scenario
Market share analysis
Other prominent vendors

PART 17: Key vendor analysis
Amgen
Bristol-Myers Squibb
Novartis

PART 18: Appendix
List of abbreviation

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global acute lymphocytic leukemia therapeutics market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global acute lymphocytic leukemia therapeutics market by geography 2014
Exhibit 05: Global acute lymphocytic leukemia therapeutics market revenue by geography 2014-2019 ($ millions)
Exhibit 06: Global acute lymphocytic leukemia therapeutics market revenue by geography (percentage)
Exhibit 07: Acute lymphocytic leukemia market in Americas 2014-2019 ($ millions)
Exhibit 08: Acute lymphocytic leukemia market in EMEA 2014-2019 ($ millions)
Exhibit 09: Acute lymphocytic leukemia market in APAC 2014-2019 ($ millions)
Exhibit 10: Impact of drivers
Exhibit 11: Impact of drivers and challenges
Exhibit 12: Key takeaways: Amgen
Exhibit 13: Global sales of Sprycel 2012-2014 ($ millions)
Exhibit 14: Key takeaways: Bristol-Myers Squibb
Exhibit 15: Global sales of Gleevec/Glivec 2012-2014 ($ millions)
Exhibit 16: Key takeaways: Novartis
Exhibit 17: Amgen: Business segmentation by revenue 2014
Exhibit 18: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 19: Amgen: Geographical segmentation by revenue 2014
Exhibit 20: Business segmentation by revenue 2013 and 2014 ($ billions)



【掲載企業】

Amgen, Bristol-Myers Squibb, Novartis, Ariad, Arno Therapeutics, Baxter, Boehringer Ingelheim, ERYTECH Pharma, Fate Therapeutics, Jazz Pharmaceuticals, Orphan Europe, Otsuka, Ono Pharmaceuticals, Onconova Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals.

【資料のキーワード】

急性リンパ性白血病(ALL)、急性リンパ芽球性白血病、治療薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[急性リンパ性白血病/急性リンパ芽球性白血病治療薬の世界市場] (Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019 / IRTNTR7891)販売に関する免責事項
[急性リンパ性白血病/急性リンパ芽球性白血病治療薬の世界市場] (Global Acute Lymphocytic/Lymphoblastic leukemia Market 2015-2019 / IRTNTR7891)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆